SANJAY MATHEW to Receptors, N-Methyl-D-Aspartate
This is a "connection" page, showing publications SANJAY MATHEW has written about Receptors, N-Methyl-D-Aspartate.
Connection Strength
1.671
-
Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trial. Depress Anxiety. 2021 11; 38(11):1108-1119.
Score: 0.695
-
Targeting glutamate signalling in depression: progress and prospects. Nat Rev Drug Discov. 2017 Jul; 16(7):472-486.
Score: 0.515
-
Does mismatch negativity have utility for NMDA receptor drug development in depression? Braz J Psychiatry. 2022 Jan-Feb; 44(1):61-73.
Score: 0.179
-
Ketamine for depression clinical issues. Adv Pharmacol. 2020; 89:131-162.
Score: 0.159
-
Glutamate and anxiety disorders. Curr Psychiatry Rep. 2007 Aug; 9(4):278-83.
Score: 0.066
-
A randomized cross-over trial to define neurophysiological correlates of AV-101 N-methyl-D-aspartate receptor blockade in healthy veterans. Neuropsychopharmacology. 2021 03; 46(4):820-827.
Score: 0.042
-
Neurobiology of anxiety disorders and implications for treatment. Mt Sinai J Med. 2006 Nov; 73(7):941-9.
Score: 0.016